查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2028344

鐮狀細胞疾病治療市場規模、佔有率、成長及全球產業分析：按類型、應用和地區分類的洞察，2026-2034 年預測

Sickle Cell Disease Treatment Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 103 Pages | 商品交期: 請詢問到貨日

價格

鐮狀細胞疾病 (SCD) 治療市場的成長要素

全球鐮狀細胞疾病（SCD）治療市場預計在2025年達到39.4億美元，2026年成長至47.3億美元，2034年達到204.7億美元。該市場正經歷強勁成長，主要受疾病盛行率上升、公眾認知度提高以及治療方法進步的推動。美國將引領市場，預計2025年將佔63.35%的市場佔有率，這得益於其完善的醫療基礎設施、較高的診斷率以及持續的藥物研發投入。

鐮狀細胞疾病是一種遺傳性血液疾病，會影響血紅素，導致紅血球異常、氧氣供應減少，並引發貧血、疼痛發作和器官損傷等併發症。治療方法包括輸血、藥物治療和骨髓移植，近年來，人們越來越重視先進的治療方法。

市場趨勢

市場上最顯著的趨勢之一是基因療法的日益普及。基因療法透過糾正基因突變來解決疾病的根本原因，有望實現長期甚至永久治療。包括使用 CRISPR 技術的治療方法在內的多項臨床試驗正在進行中，並已顯示出令人鼓舞的結果。

另一個重要趨勢是越來越重視創新藥物的研發。製藥公司正大力投資研發，以推出能夠緩解血管閉塞性疾病（VOCs）等併發症的新治療方法。近期核准的藥物和正在研發中的候選藥物有望徹底改變現有的治療標準。

此外，人們對個人化醫療和標靶治療的興趣日益濃厚，這些治療旨在改善患者預後並減少治療相關併發症。

促進因素

該市場的主要驅動力是全球鐮狀細胞疾病（ 鐮狀）盛行率的不斷上升。據估計，全球有數百萬人受到影響，其中非洲、美國和印度等地區的盛行率較高。光是在美國，就有約10萬人患有鐮狀細胞疾病（SCD）。

另一個主要因素是疾病併發症（例如閉塞性發作）的嚴重程度和發生頻率不斷增加。患者可能每年經歷多次發作，這增加了對有效治療方法和緊急醫療護理的需求。

新治療方法的推出和監管支持也在加速市場成長。美國食品藥物管理局（FDA）和歐洲藥品管理局（EMA）等監管機構為創新藥物提供快速核准，鼓勵製藥公司擴大產品平臺。

此外，人們對這種疾病的認知不斷提高，以及政府為改善診斷和治療途徑而採取的舉措，也促進了市場的擴張。

抑制因子

儘管成長前景強勁，但由於發展中地區治療選擇有限，市場面臨許多挑戰。許多國家缺乏先進治療方法和羥基尿素等基本藥物。

另一個主要阻礙因素是治療費用高。先進的治療方法，特別是基因療法和骨髓移植，價格昂貴，限制了許多患者獲得這些療法的機會。

此外，某些地區認知度低和醫療基礎設施不足持續阻礙市場成長。

細分分析

就治療方法而言，市場細分為輸血、骨髓移植和藥物治療。輸血因其在治療中風等嚴重併發症的有效性，佔了最大的市場佔有率。然而，由於新藥的問世和先進治療方法的日益普及，藥物治療預計將快速成長。

從終端用戶來看，市場可分為醫院、專科診所和其他機構。醫院憑藉其龐大的住院患者數量和設備齊全的先進治療設施，在該領域佔主導地位。專科診所也因對專科護理需求的不斷成長和患者偏好的改變而發展迅速。

區域分析

美國引領全球市場，預計到 2025 年將達到 24.9 億美元，到 2026 年將達到 30 億美元，這得益於積極的研究、較高的治療可及性和持續的產品核可。

歐洲佔了較大的市場佔有率，這得益於有利的報銷政策和意識提升。該地區各國正致力於擴大治療覆蓋範圍和改善醫療基礎設施。

由於鐮狀細胞疾病的高發病率和日益增多的宣傳活動，預計中東和非洲地區將顯著成長。然而，醫療資源匱乏仍是一個挑戰。

主要公司及趨勢

市場上的主要參與者包括輝瑞（全球血液治療公司）、諾華、Emmaus Medical、Bluebird Bio、Agios Pharmaceuticals 和百時美施貴寶。這些公司專注於開發創新治療方法並企業發展。

近期發展包括策略合作、產品核准和業務拓展計劃，旨在改善治療途徑並滿足未滿足的需求。

目錄

第1章：引言

第2章摘要整理

第3章 市場動態

  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場趨勢

第4章：主要考慮因素

  • 2025年主要國家及地區鐮狀細胞病患疾病率
  • 概述 - 品牌藥品（非處方藥）
  • 管道分析，主要公司
  • 新產品發布
  • 產業重大發展動態（合併、收購、合作等）
  • 新冠疫情對市場的影響

第5章：2021-2034年全球鐮狀細胞疾病治療市場分析、洞察與預測

  • 市場分析、洞察與預測：按治療方法
    • 骨髓移植
    • 輸血
    • 藥物治療
      • 羥基尿素
      • 品牌產品
  • 市場分析、洞察與預測：按最終用戶分類
    • 醫院
    • 專科診所
    • 其他
  • 市場分析、洞察與預測：按國家和地區分類
    • 美國
    • 歐洲
    • 世界其他地區

第6章：美國鐮狀細胞疾病治療市場分析、洞察與預測（2021-2034年）

第7章：歐洲鐮狀細胞疾病治療市場分析、洞察與預測（2021-2034年）

第8章：2021-2034年全球鐮狀細胞疾病治療市場分析、洞察及對其他地區的預測

第9章 競爭分析

  • 全球市佔率分析（2025 年）
  • 公司簡介
    • Bristol-Myers Squibb Company
    • Addmedica
    • Novartis AG
    • Global Blood Therapeutics, Inc.（Pfizer Inc.）
    • Emmaus Medical, Inc.
    • bluebird bio Inc.
    • Agios Pharmaceuticals, Inc.
Product Code: FBI101009

Growth Factors of sickle cell disease (SCD) treatment Market

The global sickle cell disease (SCD) treatment market was valued at USD 3.94 billion in 2025 and increased to USD 4.73 billion in 2026, with projections indicating it will reach USD 20.47 billion by 2034. The market is experiencing strong growth due to rising disease prevalence, increasing awareness, and advancements in treatment options. The United States dominated the market with a 63.35% share in 2025, supported by strong healthcare infrastructure, high diagnosis rates, and continuous drug development initiatives.

Sickle cell disease is a genetic blood disorder that affects hemoglobin, leading to abnormal red blood cells, reduced oxygen flow, and complications such as anemia, pain crises, and organ damage. Treatment approaches include blood transfusion, pharmacotherapy, and bone marrow transplantation, with increasing focus on advanced therapies.

Market Trends

One of the most significant trends in the market is the growing adoption of gene therapy. Gene therapy targets the root cause of the disease by correcting genetic mutations, offering the potential for long-term or permanent treatment. Several clinical trials, including CRISPR-based therapies, are progressing and showing promising outcomes.

Another key trend is the increasing focus on innovative drug development. Pharmaceutical companies are investing heavily in research and development to introduce new therapies that reduce complications such as vaso-occlusive crises (VOCs). Recently approved drugs and pipeline candidates are expected to transform treatment standards.

Additionally, there is a rising emphasis on personalized medicine and targeted therapies, which aim to improve patient outcomes and reduce treatment-related complications.

Driving Factors

The market is primarily driven by the increasing prevalence of sickle cell disease globally. According to estimates, millions of individuals are affected worldwide, with a significant patient population in regions such as Africa, the U.S., and India. In the U.S. alone, approximately 100,000 individuals are affected by SCD.

Another major driver is the growing severity and frequency of disease complications, such as vaso-occlusive crises. Patients can experience multiple episodes annually, increasing the demand for effective treatment solutions and emergency care.

The introduction of novel therapies and regulatory support is also accelerating market growth. Agencies such as the U.S. FDA and European Medicines Agency are providing fast-track approvals for innovative drugs, encouraging pharmaceutical companies to expand their product pipelines.

Furthermore, increasing awareness and government initiatives aimed at improving diagnosis and treatment access are contributing to market expansion.

Restraining Factors

Despite strong growth prospects, the market faces challenges due to the limited availability of treatment options in developing regions. Many countries lack access to advanced therapies and essential medications such as hydroxyurea.

Another major restraint is the high cost of treatment, particularly for advanced therapies such as gene therapy and bone marrow transplantation, which limits accessibility for a large patient population.

Additionally, lack of awareness and inadequate healthcare infrastructure in certain regions continue to hinder market growth.

Segmentation Analysis

By treatment modality, the market is segmented into blood transfusion, bone marrow transplant, and pharmacotherapy. The blood transfusion segment holds the largest share due to its effectiveness in managing severe complications such as stroke. However, pharmacotherapy is expected to grow rapidly due to the introduction of new drugs and increasing adoption of advanced treatments.

By end-user, the market includes hospitals, specialty clinics, and others. Hospitals dominate the segment due to the high number of patient admissions and availability of advanced treatment facilities. Specialty clinics are also gaining traction due to specialized care and increasing patient preference.

Regional Analysis

The United States leads the global market with a valuation of USD 2.49 billion in 2025 and USD 3.00 billion in 2026, driven by strong research activities, high treatment accessibility, and continuous product approvals.

Europe holds a significant share, supported by favorable reimbursement policies and increasing patient awareness. Countries in the region are focusing on expanding treatment accessibility and improving healthcare infrastructure.

The Middle East & Africa region is expected to witness notable growth due to the high prevalence of SCD and increasing awareness initiatives. However, limited healthcare resources remain a challenge.

Key Industry Players and Developments

Major players in the market include Pfizer Inc. (Global Blood Therapeutics), Novartis AG, Emmaus Medical, bluebird bio Inc., Agios Pharmaceuticals, and Bristol-Myers Squibb Company. These companies are focusing on developing innovative therapies and expanding their global presence.

Recent developments include strategic partnerships, product approvals, and expansion programs aimed at improving treatment accessibility and addressing unmet medical needs.

Conclusion

The sickle cell disease treatment market is projected to grow from USD 3.94 billion in 2025 to USD 20.47 billion by 2034, driven by rising disease prevalence, advancements in gene therapy, and increasing investment in drug development. While challenges such as high treatment costs and limited access in developing regions persist, ongoing innovation and regulatory support are expected to significantly transform the treatment landscape in the coming years.

Segmentation By Treatment Modality, End-user, and Geography

By Treatment Modality * Bone Marrow Transplant

  • Blood Transfusion
  • Pharmacotherapy
    • Hydroxyurea
    • Branded Products
  • Endari
  • Adakveo
  • Oxbryta
  • Zynteglo
  • PYRUKYND (Mitapivat)
  • CTX001
  • Inclacumab
  • MGTA-145
  • Vamifeport (VIT-2763)
  • ALXN1820
  • FT-4202
  • GBT021601

By End-user

Hospitals

  • Specialty Clinics
  • Others

By Geography * U.S. (By Treatment Modality and End-user)

  • Europe (By Treatment Modality, End-user, and Country/Sub-region)
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Scandinavia
    • Rest of Europe
  • Rest of the World (By Treatment Modality, End-user, and Country/Sub-region)
    • India
    • China
    • Japan
    • GCC Countries
    • Rest of ROW

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Prevalence of Sickle Cell Disease, For Key Countries/ Regions, 2025
  • 4.2. Overview - Branded Drugs (Marketed)
  • 4.3. Pipeline Analysis, Key Players
  • 4.4. New Product Launches
  • 4.5. Key Industry Developments (Mergers, Acquisitions, Partnership; etc.)
  • 4.6. Impact of COVID-19 on the Market

5. Global Sickle Cell Disease Treatment Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Treatment Modality
    • 5.1.1. Bone Marrow Transplant
    • 5.1.2. Blood Transfusion
    • 5.1.3. Pharmacotherapy
      • 5.1.3.1. Hydroxyurea
      • 5.1.3.2. Branded Products
        • 5.1.3.2.1. Endari
        • 5.1.3.2.2. Adakveo
        • 5.1.3.2.3. Oxbryta
        • 5.1.3.2.4. PYRUKYND (Mitapivat)
        • 5.1.3.2.5. Zynteglo
        • 5.1.3.2.6. CTX001
        • 5.1.3.2.7. Inclacumab
        • 5.1.3.2.8. Vamifeport (VIT-2763)
        • 5.1.3.2.9. ALXN1820
        • 5.1.3.2.10. MGTA-145
        • 5.1.3.2.11. FT-4202
        • 5.1.3.2.12. GBT021601
  • 5.2. Market Analysis, Insights and Forecast - By End-user
    • 5.2.1. Hospitals
    • 5.2.2. Specialty Clinics
    • 5.2.3. Others
  • 5.3. Market Analysis, Insights and Forecast - By Country/Region
    • 5.3.1. U.S.
    • 5.3.2. Europe
    • 5.3.3. Rest of the World

6. U.S. Sickle Cell Disease Treatment Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Treatment Modality
    • 6.1.1. Bone Marrow Transplant
    • 6.1.2. Blood Transfusion
    • 6.1.3. Pharmacotherapy
      • 6.1.3.1. Hydroxyurea
      • 6.1.3.2. Branded Products
        • 6.1.3.2.1. Endari
        • 6.1.3.2.2. Adakveo
        • 6.1.3.2.3. Oxbryta
        • 6.1.3.2.4. PYRUKYND (Mitapivat)
        • 6.1.3.2.5. Zynteglo
        • 6.1.3.2.6. CTX001
        • 6.1.3.2.7. Inclacumab
        • 6.1.3.2.8. Vamifeport (VIT-2763)
        • 6.1.3.2.9. ALXN1820
        • 6.1.3.2.10. MGTA-145
        • 6.1.3.2.11. FT-4202
        • 6.1.3.2.12. GBT021601
  • 6.2. Market Analysis, Insights and Forecast - By End-user
    • 6.2.1. Hospitals
    • 6.2.2. Specialty Clinics
    • 6.2.3. Others

7. Europe Sickle Cell Disease Treatment Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Treatment Modality
    • 7.1.1. Bone Marrow Transplant
    • 7.1.2. Blood Transfusion
    • 7.1.3. Pharmacotherapy
      • 7.1.3.1. Hydroxyurea
      • 7.1.3.2. Branded Products
        • 7.1.3.2.1. Endari
        • 7.1.3.2.2. Adakveo
        • 7.1.3.2.3. Oxbryta
        • 7.1.3.2.4. PYRUKYND (Mitapivat)
        • 7.1.3.2.5. Zynteglo
        • 7.1.3.2.6. CTX001
        • 7.1.3.2.7. Inclacumab
        • 7.1.3.2.8. Vamifeport (VIT-2763)
        • 7.1.3.2.9. ALXN1820
        • 7.1.3.2.10. MGTA-145
        • 7.1.3.2.11. FT-4202
        • 7.1.3.2.12. GBT021601
  • 7.2. Market Analysis, Insights and Forecast - By End-user
    • 7.2.1. Hospitals
    • 7.2.2. Specialty Clinics
    • 7.2.3. Others

8. Rest of the World Sickle Cell Disease Treatment Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Treatment Modality
    • 8.1.1. Bone Marrow Transplant
    • 8.1.2. Blood Transfusion
    • 8.1.3. Pharmacotherapy
      • 8.1.3.1. Hydroxyurea
      • 8.1.3.2. Branded Products
        • 8.1.3.2.1. Endari
        • 8.1.3.2.2. Adakveo
        • 8.1.3.2.3. Oxbryta
        • 8.1.3.2.4. PYRUKYND (Mitapivat)
        • 8.1.3.2.5. Zynteglo
        • 8.1.3.2.6. CTX001
        • 8.1.3.2.7. Inclacumab
        • 8.1.3.2.8. Vamifeport (VIT-2763)
        • 8.1.3.2.9. ALXN1820
        • 8.1.3.2.10. MGTA-145
        • 8.1.3.2.11. FT-4202
        • 8.1.3.2.12. GBT021601
  • 8.2. Market Analysis, Insights and Forecast - By End-user
    • 8.2.1. Hospitals
    • 8.2.2. Specialty Clinics
    • 8.2.3. Others

9. Competitive Analysis

  • 9.1. Global Market Share Analysis (2025)
  • 9.2. Company Profiles
    • 9.2.1. Bristol-Myers Squibb Company
      • 9.2.1.1. Overview
      • 9.2.1.2. Product
      • 9.2.1.3. SWOT Analysis
      • 9.2.1.4. Recent Developments
      • 9.2.1.5. Strategies
      • 9.2.1.6. financials (Based on Availability)
    • 9.2.2. Addmedica
      • 9.2.2.1. Overview
      • 9.2.2.2. Product
      • 9.2.2.3. SWOT Analysis
      • 9.2.2.4. Recent Developments
      • 9.2.2.5. Strategies
      • 9.2.2.6. financials (Based on Availability)
    • 9.2.3. Novartis AG
      • 9.2.3.1. Overview
      • 9.2.3.2. Product
      • 9.2.3.3. SWOT Analysis
      • 9.2.3.4. Recent Developments
      • 9.2.3.5. Strategies
      • 9.2.3.6. financials (Based on Availability)
    • 9.2.4. Global Blood Therapeutics, Inc. (Pfizer Inc.)
      • 9.2.4.1. Overview
      • 9.2.4.2. Product
      • 9.2.4.3. SWOT Analysis
      • 9.2.4.4. Recent Developments
      • 9.2.4.5. Strategies
      • 9.2.4.6. financials (Based on Availability)
    • 9.2.5. Emmaus Medical, Inc.
      • 9.2.5.1. Overview
      • 9.2.5.2. Product
      • 9.2.5.3. SWOT Analysis
      • 9.2.5.4. Recent Developments
      • 9.2.5.5. Strategies
      • 9.2.5.6. financials (Based on Availability)
    • 9.2.6. bluebird bio Inc.
      • 9.2.6.1. Overview
      • 9.2.6.2. Product
      • 9.2.6.3. SWOT Analysis
      • 9.2.6.4. Recent Developments
      • 9.2.6.5. Strategies
      • 9.2.6.6. financials (Based on Availability)
    • 9.2.7. Agios Pharmaceuticals, Inc.
      • 9.2.7.1. Overview
      • 9.2.7.2. Product
      • 9.2.7.3. SWOT Analysis
      • 9.2.7.4. Recent Developments
      • 9.2.7.5. Strategies
      • 9.2.7.6. financials (Based on Availability)

List of Tables

  • Table 01: Global Sickle Cell Disease Treatment Market Revenue (USD billion) Forecast, By Treatment Modality, 2021-2034
  • Table 02: Global Sickle Cell Disease Treatment Market Revenue (USD billion) Forecast, By Pharmacotherapy, 2021-2034
  • Table 03: Global Sickle Cell Disease Treatment Market Revenue (USD billion) Forecast, By Branded Products, 2021-2034
  • Table 04: Global Sickle Cell Disease Treatment Market Revenue (USD billion) Forecast, By End-user, 2021-2034
  • Table 05: Global Sickle Cell Disease Treatment Market Revenue (USD billion) Forecast, By Geography, 2021-2034
  • Table 06: U.S. Sickle Cell Disease Treatment Market Revenue (USD billion) Forecast, By Treatment Modality, 2021-2034
  • Table 07: U.S. Sickle Cell Disease Treatment Market Revenue (USD billion) Forecast, By Pharmacotherapy, 2021-2034
  • Table 08: U.S. Sickle Cell Disease Treatment Market Revenue (USD billion) Forecast, By Branded Products, 2021-2034
  • Table 09: U.S. Sickle Cell Disease Treatment Market Revenue (USD billion) Forecast, By End-user, 2021-2034
  • Table 10: Europe Sickle Cell Disease Treatment Market Revenue (USD billion) Forecast, By Treatment Modality, 2021-2034
  • Table 11: Europe Sickle Cell Disease Treatment Market Revenue (USD billion) Forecast, By Pharmacotherapy, 2021-2034
  • Table 12: Europe Sickle Cell Disease Treatment Market Revenue (USD billion) Forecast, By Branded Products, 2021-2034
  • Table 13: Europe Sickle Cell Disease Treatment Market Revenue (USD billion) Forecast, By End-user, 2021-2034
  • Table 14: Rest of the World Sickle Cell Disease Treatment Market Revenue (USD billion) Forecast, By Treatment Modality, 2021-2034
  • Table 15: Rest of the World Sickle Cell Disease Treatment Market Revenue (USD billion) Forecast, By Pharmacotherapy, 2021-2034
  • Table 16: Rest of the World Sickle Cell Disease Treatment Market Revenue (USD billion) Forecast, By Branded Products, 2021-2034
  • Table 17: Rest of the World Sickle Cell Disease Treatment Market Revenue (USD billion) Forecast, By End-user, 2021-2034

List of Figures

  • Figure 01: Global Sickle Cell Disease Treatment Market Revenue Breakdown (USD billion, %) by Geography, 2025 & 2034
  • Figure 02: Global Sickle Cell Disease Treatment Market Value Share (%), By Treatment Modality, 2025 & 2034
  • Figure 03: Global Sickle Cell Disease Treatment Market Value Share (%), By End-user, 2025 & 2034
  • Figure 04: Global Sickle Cell Disease Treatment Market Value Share (%), By Geography, 2025 & 2034
  • Figure 05: U.S. Sickle Cell Disease Treatment Market Value (USD billion), by Treatment Modality, 2025 & 2034
  • Figure 06: U.S. Sickle Cell Disease Treatment Market Value Share (%), by Treatment Modality, 2025
  • Figure 07: U.S. Sickle Cell Disease Treatment Market Value (USD billion), by End-user, 2025 & 2034
  • Figure 08: U.S. Sickle Cell Disease Treatment Market Value Share (%), by End-user, 2025
  • Figure 09: Europe Sickle Cell Disease Treatment Market Value (USD billion), by Treatment Modality, 2025 & 2034
  • Figure 10: Europe Sickle Cell Disease Treatment Market Value Share (%), by Treatment Modality, 2025
  • Figure 11: Europe Sickle Cell Disease Treatment Market Value (USD billion), by End-user, 2025 & 2034
  • Figure 12: Europe Sickle Cell Disease Treatment Market Value Share (%), by End-user, 2025
  • Figure 13: Rest of the World Sickle Cell Disease Treatment Market Value (USD billion), by Treatment Modality, 2025 & 2034
  • Figure 14: Rest of the World Sickle Cell Disease Treatment Market Value Share (%), by Treatment Modality, 2025
  • Figure 15: Rest of the World Sickle Cell Disease Treatment Market Value (USD billion), by End-user, 2025 & 2034
  • Figure 16: Rest of the World Sickle Cell Disease Treatment Market Value Share (%), by End-user, 2025
  • Figure 17: Global Sickle Cell Disease Treatment Market Share (%), by Company, 2025